Project Grant HT94252410055
Award Date
1/15/24
Completion Date
1/14/27
Dollars Obligated
$839K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19111, USA
Similar Awards
The Department of Defense (DoD) has awarded a $846,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Institute For Cancer Research, a non-profit research organization, to investigate PALB2 mutant breast cancer. The funding supports a 3-year research project from August 1, 2024 to July 31, 2027. As the prime grantee, The Institute For Cancer Research will conduct innovative scientific studies and clinical trials focused on developing new treatments...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,128,000 Project Grant to The Institute For Cancer Research to conduct research on "Restoring PALB2 Function as a Mechanism of PARP1 Resistance in BRCA1-Mutant EOC". The award, with a performance period from July 1, 2024 to June 30, 2028, supports innovative scientific research aimed at improving health outcomes for military service members, veterans, and the broader...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,301,250.00 to Health Research, Inc. to conduct research aimed at "Inhibiting MDSC Biogenesis to Augment Immunotherapy Efficacy in Triple-Negative Breast Cancer". The 3-year award, beginning on March 1, 2025 and ending on February 29, 2028, will support advanced biomedical research to transform healthcare for military service members and the...
The U.S. Defense Health Agency awarded a $907,170 Project Grant to the Provincial Health Services Authority (operating as BC Cancer) in Canada. This grant, provided under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), supports research on therapeutic targeting of genomic instability in triple-negative breast cancer. The 3-year project, running from September 2023 to September 2026, aims to advance the understanding and treatment of this aggressive...
The Baylor College of Medicine will use a $1.6 million Project Grant from the Defense Health Agency to research germline variants and population-wide breast cancer risk. The grant was awarded on February 1, 2023 under the Military Medical Research and Development program (CFDA 12.420). Through basic, applied, and advanced biomedical research, this project aims to transform healthcare for service members and the public by investigating medical solutions for the battlefield and developing...
This $1,535,039 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development Program (CFDA 12.420) supports research conducted by Wake Forest University Health Sciences (WFUHS) to study how the breast tissue microbiota regulates immune checkpoint blockade therapy responsiveness in triple-negative breast cancer. The research aims to advance scientific understanding and develop new treatment approaches for this aggressive form of breast cancer that...
The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...
This Project Grant award, valued at $800,643.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Beckman Research Institute of the City of Hope. The award supports advanced biomedical research aimed at transforming healthcare for military service members and the broader public, with a specific focus on investigating the role of peptidylarginine deiminases in mediating immune evasion of triple-negative breast cancer. The...
This $871,016 Project Grant awarded on January 1, 2024 by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to the Beckman Research Institute of the City of Hope supports research on a highly tumor-specific oncolytic virus combined with a viral protein-target T cell engager for the treatment of triple-negative breast cancer. The grant aims to develop innovative therapies for this aggressive form of breast cancer that impacts military personnel and veterans. As a...